-
公开(公告)号：US10894814B2
公开(公告)日：2021-01-19
申请号：US15826442
申请日：2017-11-29
Applicant: Amgen Inc.
Inventor： Yumei Xiong , Yi Zhang , Jackie Z. Sheng , Agnes Eva Hamburger , Murielle M. Veniant-Ellison , Grant Shimamoto , Xiaoshan Min , Zhulun Wang , Jie Tang , Gunasekaran Kannan , Marissa Mock , Kenneth William Walker
IPC: C07K14/475
Abstract: Constructs comprising GDF15, and mutants thereof are provided. In various embodiments the constructs comprising GDF15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
-
公开(公告)号：US10562950B2
公开(公告)日：2020-02-18
申请号：US15893451
申请日：2018-02-09
Applicant: AMGEN INC.
Inventor： Gunasekaran Kannan
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US20190046611A1
公开(公告)日：2019-02-14
申请号：US16054035
申请日：2018-08-03
Applicant: AMGEN INC.
Inventor： Khaled M.K.Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Darren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
公开(公告)号：US20170066845A1
公开(公告)日：2017-03-09
申请号：US15258750
申请日：2016-09-07
Applicant: Amgen Inc.
Inventor： Hailing Hsu , Ming Zhang , Gunasekaran Kannan , Frederick Jacobsen , Wayne Tsuji
IPC: C07K16/46 , A61K45/06 , A61K39/395 , C07K16/28
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Abstract translation: 本文描述了对BAFF和B7RP1特异性的双特异性蛋白质，编码这种蛋白质的核酸，制备此类蛋白质的方法以及这些蛋白质的用途。
-
公开(公告)号：US09580486B2
公开(公告)日：2017-02-28
申请号：US14209699
申请日：2014-03-13
Applicant: Amgen Inc.
Inventor： Marc A. Gavin , Gunasekaran Kannan , Li Li , Joshua T. Pearson , Margaret Karow
CPC classification number: C07K14/55 , A61K38/00 , C07K16/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
Abstract translation: 本文提供了IL-2突变蛋白和IL-2突变蛋白Fc-融合分子，其优先扩增和激活T调节细胞并且适于大规模生产。 本文还提供了缺乏或具有高度降低的效应子功能和高稳定性的变体人IgG1 Fc分子，尽管在N297缺乏糖基化。 此外，本文提供了当在哺乳动物细胞中表达时被糖基化的接头肽。
-
Patent Agency Ranking
公开(公告)号：US09458246B2
公开(公告)日：2016-10-04
申请号：US14203123
申请日：2014-03-10
Applicant: Amgen Inc.
Inventor： Hailing Hsu , Ming Zhang , Gunasekaran Kannan , Frederick W. Jacobsen , Wayne Tsuji
IPC: C07K16/28 , C07K16/46 , A61K39/395 , A61K45/06 , A61K39/00
CPC classification number: C07K16/468 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/2827 , C07K16/2875 , C07K2317/31 , C07K2317/524 , C07K2317/526 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/94 , C07K2318/10 , C07K2319/70
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Abstract translation: 本文描述了对BAFF和B7RP1特异性的双特异性蛋白质，编码这种蛋白质的核酸，制备此类蛋白质的方法以及这些蛋白质的用途。
-
公开(公告)号：US20160024225A1
公开(公告)日：2016-01-28
申请号：US14776399
申请日：2014-03-12
Applicant: AMGEN INC.
Inventor： Hailing Hsu , Ming Zhang , Gunasekaran Kannan , Frederick W. Jacobsen , Wayne Tsuji
Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
Abstract translation: 本文描述了对BAFF和B7RP1特异性的双特异性蛋白质，编码这种蛋白质的核酸，制备此类蛋白质的方法以及这些蛋白质的用途。
-
公开(公告)号：US11976103B2
公开(公告)日：2024-05-07
申请号：US17065395
申请日：2020-10-07
Applicant: Amgen Inc.
Inventor： Eric Alan Butz , Christy Ann Thomson , Marc Alain Gavin , Ian Nevin Foltz , Dong Xia , Dina N. Alcorn , Randal Robert Ketchem , Ai Ching Lim , Kathy Manchulenko , Laura Sekirov , Kelly Ann Berry , Cyr Clovis Chua De Imus , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Li Li
CPC classification number: C07K14/55 , A61K38/2013 , A61P37/00 , C07K16/246 , C07K2317/21 , C07K2317/41 , C07K2317/524 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/30
Abstract: Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also provided herein are linker peptides that are glycosylated when expressed in mammalian cells. Also provided herein are methods of making and using the compositions of the present invention.
-
公开(公告)号：US11976102B2
公开(公告)日：2024-05-07
申请号：US17063566
申请日：2020-10-05
Applicant: Amgen Inc.
Inventor： Marc Alain Gavin , Gunasekaran Kannan , Li Li , Joshua Thomas Pearson , Margaret Karow
CPC classification number: C07K14/55 , C07K16/00 , A61K38/00 , C07K2317/41 , C07K2317/52 , C07K2317/524 , C07K2317/71 , C07K2317/94 , C07K2319/21 , C07K2319/30 , C07K2319/43
Abstract: Provided herein are IL-2 muteins and IL-2 mutein Fc-fusion molecules that preferentially expand and activate T regulatory cells and are amenable to large scale production. Also provided herein are variant human IgG1 Fc molecules lacking or with highly reduced effector function and high stability despite lacking glycosylation at N297. Also, provided herein are linker peptides that are glycosylated when expressed in mammalian cells.
-
公开(公告)号：US11541103B2
公开(公告)日：2023-01-03
申请号：US16054035
申请日：2018-08-03
Applicant: AMGEN INC.
Inventor： Khaled M. K. Z. Ali , Neeraj Jagdish Agrawal , Gunasekaran Kannan , Ian Foltz , Zhulun Wang , Darren Bates , Marissa Mock , Shunsuke Takenaka
Abstract: Provided herein are IL-21 muteins and fusion proteins comprising the same for use in methods of treating a disease. Related conjugates, nucleic acids, vectors, host cells, pharmaceutical compositions and kits are also provided herein. Methods of making the IL-21 muteins and fusion proteins comprising the same, as well as methods of treating a subject in need thereof, are provided by the present disclosure. Further provided are PD-1 antigen-binding proteins.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.025 seconds)
